NYXH Nyxoah

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares

REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont-Saint-Guibert (Belgium), October 29, 2021, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the exercise of subscription rights and the issue of new shares.

  •  Share capital: EUR 4,407,612.69
  •  Total number of securities carrying voting rights: 25,657,359 (all ordinary shares) 
  •  Total number of voting rights (= denominator): 25,657,359 (all relating to ordinary shares)  
  •  Number of rights to subscribe to securities carrying voting rights not yet issued: 
    •  90 “2013 ESOP Warrants” issued on May 3, 2013 and 23 December 2014, entitling their holders to subscribe to a total number of 45,000 securities carrying voting rights (all ordinary shares); 
    •  205 “2016 ESOP Warrants” issued on November 3, 2016, entitling their holders to subscribe to a total number of 102,500 securities carrying voting rights (all ordinary shares); 
    •  100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);  
    •  510,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 510,500 securities carrying voting rights (all ordinary shares); and
    •  1,400,000 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,400,000 securities carrying voting rights (all ordinary shares). 

*

*        *

For further information, please contact:

Nyxoah

Jeremy Feffer, VP IR and Corporate Communications



Gilmartin Group

Vivian Cervantes



Attachment



EN
29/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $...

Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $77 Millions pour Supporter la Commercialisation de Genio aux États-Unis INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $77 Millions pour Supporter la Commercialisation de Genio aux États-Unis Les financements consistent des investissements d’equity, notamment de ResMed, Cochlear et le Chairman et le management de Nyxoah, et une obligation convertible. Mont-Saint-Guibert, Belgique – 14 novembre 2025, 8h00 CET / 2h00 ET – Nyxoah SA (Euronext Bruxell...

 PRESS RELEASE

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Driv...

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio INSIDE INFORMATIONREGULATED INFORMATION Correction and ReplacementNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the private placemen...

 PRESS RELEASE

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Driv...

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. Mont-Saint-Guibert, Belgium – November 13, 2025, 2025, 10:11pm CET / 4:11 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the develo...

 PRESS RELEASE

Nyxoah Reports Third Quarter 2025 Financial and Operating Results

Nyxoah Reports Third Quarter 2025 Financial and Operating Results REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financia...

 PRESS RELEASE

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Tr...

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2025 INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2025 Lancement réussi aux États-Unis. Les premières implantations commerciales de Genio, largement prises en charge par les organismes payeurs, génèrent les premiers revenus. Mont-Saint-Guibert, Belgique – 13 novembre 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch